peginterferon beta-1a
Trade name: Plegridy
Recombinant proteinapproved
Approved
Aug 15, 2014
Clinical trial activity
54 trials · 66 clinical orgs · 2 marketing orgs
Phase 1
12
Phase 2
34
Phase 3
19
Phase 4
9
Earliest trial started Aug 1, 1998 (NCT00004450)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2000s
2010s
- Aug 15, 2014
Earliest FDA Approval
- Aug 15, 2014
Biogen-IDEC — Marketing Organization
- Aug 15, 2014
Biogen-IDEC — NDA Secondary Org
Indications
Approved for
Studied for
- Acute Lung Injury · Phase 1/Phase 2
- Astrocytoma · Phase 1
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Coronavirus Infections · Phase 3
- COVID-19 · Phase 4
- Glioblastoma · Phase 1
- Gliosarcoma · Phase 1
- Healthy Volunteers · Phase 1
- Hepatitis C, Chronic · Phase 3
- Interferons · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 4
- Macular Edema · Phase 3
- Melanoma · Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 1
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Pharmacokinetics · Phase 1
- Renal Insufficiency · Phase 1
- Respiratory Distress Syndrome · Phase 1/Phase 2
- Severe Acute Respiratory Syndrome · Phase 3
- Therapeutic Equivalency · Phase 1
- Uveitis, Intermediate · Phase 3
Mechanism of action
Interferon alpha/beta receptor agonist
- Interferon betaSupplementation
IFNB1 supplementation
Approval history
- approvedAug 15, 2014
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- NCATSI8309403R0 ↗
- ChEMBLCHEMBL2108677 ↗
Also known as
- biib017
- biib017
- peg ifn-beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- peginterferon beta-1a
- pegylated interferon beta-1a
- plegridy
- plegridy
- plegridy
- polyethylene glycol-interferon beta-1a
- polyethylene glycol-interferon-beta-1a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04860518 | Phase 2 | Aug 23, 2021 | Deaconess Medical Center, Spokane, Washington, Faron Pharmaceuticals Ltd, University of Colorado |
| NCT04647669 | Phase 3 | Feb 1, 2021 | University of The West Indies |
| NCT04552379 | Phase 3 | Dec 1, 2020 | Pontificia Universidad Catolica de Chile, Telethon Kids Institute, University of Toronto, University of Western Australia |
| NCT04492475 | Phase 3 | Aug 4, 2020 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04350671 | Phase 4 | Apr 15, 2020 | Shahid Beheshti University of Medical Sciences |
| NCT04350684 | Phase 4 | Apr 15, 2020 | Shahid Beheshti University of Medical Sciences |
| NCT04343768 | Phase 4 | Apr 10, 2020 | Shahid Beheshti University of Medical Sciences |
| NCT04183491 | Phase 1 | Mar 31, 2020 | Food and Drug Administration, Spaulding Clinical Research Inc. |
| NCT04315948 | Phase 3 | Mar 22, 2020 | Institut National de la Santé Et de la Recherche Médicale, France, University of Lyon |
| NCT04079088 | Phase 2 | Dec 19, 2019 | Biogen |
| NCT03958877 | Phase 3 | Oct 3, 2019 | Biogen |
| NCT04032158 | Phase 3 | Aug 19, 2019 | Merck KGaA, Merck Serono |
| NCT04032171 | Phase 3 | Aug 19, 2019 | Merck KGaA, Merck Serono |
| NCT03870763 | Phase 3 | Mar 19, 2019 | Biogen |
| NCT03283397 | Phase 3 | Nov 4, 2018 | Kocaeli University, MonitorCRO |
| NCT03387046 | Phase 2 | Mar 26, 2018 | Merck KGaA |
| NCT03614715 | Phase 1 | Nov 27, 2017 | Cinnagen, University of Turku |
| NCT03368664 | Phase 3 | Oct 24, 2017 | Genzyme, Sanofi |
| NCT03424733 | Phase 4 | Sep 25, 2017 | Biogen, Holy Name Medical Center, Teaneck, NJ |
| NCT03177083 | Phase 4 | Jan 30, 2017 | Biogen |
Showing 20 of 54 trials
Page 1 / 3
Organizations
Research & Development (66)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 17 | 15 | 4 | 2002 |
| Merck Serono | For profit | 5 | 3 | 2 | 2006 |
| Sanofi | For profit | 5 | 4 | 2 | 2007 |
| Merck KGaA | For profit | 4 | 2 | 2 | 2010 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2004 |
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Biocad | For profit | 2 | 2 | 2 | 2014 |
| Faron Pharmaceuticals Ltd | For profit | 2 | 2 | 1 | 2009 |
| Food and Drug Administration | Government | 2 | 2 | 2 | 1998 |
| University of Washington | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Azienda Ospedaliera G. Brotzu | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 1 | 1 | 2016 |
| BioEq | For profit | 1 | 0 | 1 | 2014 |
| Cardiff University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Celgene | For profit | 1 | 1 | 1 | 2014 |
| Cinnagen | For profit | 1 | 1 | 1 | 2017 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Deaconess Medical Center, Spokane, Washington | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Dimensione Ricerca s.r.l. | For profit | 1 | 0 | 1 | 1999 |
66 organizations
Page 1 / 4
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Biogen-IDEC | For profit | MKTG | Aug 15, 2014 |
| Biogen-IDEC | For profit | NDA2 | Aug 15, 2014 |
| Pfizer | For profit | NDA | Mar 8, 2002 |